Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective cohort study of different leuprolide depot formulations in young hormone receptor-positive breast cancer
ChiCTR2300068147Phase 4Not yet recruiting
- Sponsor
- Jinjiang Municipal Hospital
- Start
- Jan 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of leuprolide in breast cancer (2 arms), sponsored by Jinjiang Municipal Hospital. Primary endpoint: Proportion achieving estradiol ≤30 pg/mL. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
leuprolide
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2300068147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068147.